OTS514 hydrochloride is a potent inhibitor of the aurora kinase A (AURKA), an enzyme involved in cell cycle regulation, particularly during mitosis. Due to its strong inhibitory action, it has drawn significant interest in oncology research, especially in the development of anticancer therapies. It demonstrates high efficacy in suppressing the proliferation of various cancer cell lines, including those resistant to other chemotherapeutic agents.

One of the key applications of OTS514 hydrochloride is in the study and treatment of aggressive solid tumors and hematological malignancies. It has shown promising results in preclinical models of cancers such as neuroblastoma, leukemia, and certain types of lung and breast cancers. By disrupting proper spindle formation during cell division, it induces mitotic catastrophe and apoptosis in rapidly dividing tumor cells.

Its application extends to combination therapies, where it is used alongside other chemotherapeutic agents to enhance cytotoxic effects and overcome drug resistance. Researchers also utilize OTS514 hydrochloride as a tool compound to probe aurora kinase signaling pathways and understand mechanisms of mitotic regulation.

Due to its high potency, careful dosing and delivery methods are being explored to minimize toxicity to normal cells while maximizing antitumor activity. It remains primarily a research compound and is not yet approved for clinical use, but it continues to be a valuable candidate in the development of targeted cancer treatments.